Clinical Trial Update: TK-based Suicide Gene Therapy for Hepatocellular Carcinoma [Phase 1]

View source ↗

Summary

Phase 1 study of a thymidine kinase–based suicide gene therapy for hepatocellular carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• TK-based suicide gene therapy

Snippet

Sponsor: Clinica Universidad de Navarra, Universidad de Navarra | Conditions: Carcinoma, Hepatocellular | Phase 1 | Status: COMPLETED